Prostate cancer is the most common cancer diagnosed in men, with a five-year survival rate of 97%. With advancements in technology and an increase in life expectancy among patients, it is essential to take a new approach to managing prostate cancer. Dr. Christien Kluwe, a radiation oncologist at Mays Cancer Center at UT Health San Antonio, emphasized the importance of balancing disease control and quality of life in the treatment of prostate cancer.
Kluwe raised questions about the necessity of androgen deprivation therapy for all prostate cancer patients. He believes that it is crucial to identify those patients who would benefit significantly from a decrease in testosterone levels and tailor the treatment accordingly. The oncologist emphasized the importance of avoiding unnecessary treatments for patients who may not derive significant benefits from such therapies.
As part of his research, Kluwe is exploring radiation techniques like stereotactic body radiation therapy. This treatment method is highly precise and powerful, allowing for the delivery of high doses of radiation in a shorter period. Kluwe explained how this new technique has transformed the treatment of prostate cancer by condensing an eight-week treatment regimen into just five days, with minimal impact on healthy surrounding tissues.
With tiny pellets that are only grains of rice in size, radiation can be delivered directly to the cancer cells over five days. This innovative approach to treatment has revolutionized patient outcomes by offering a more efficient and effective method of managing prostate cancer.
The collaboration between TPR and The University of Texas Health Science Center at San Antonio aims to highlight scientific advancements in medicine that have the potential to improve patient outcomes.
